Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 50 of 860

TitleReference numberPublishedLast updated
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitableTA1097
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisTA1096
Tirzepatide for managing overweight and obesityTA1026
Tirzepatide for treating type 2 diabetesTA924
Guselkumab for treating moderately to severely active ulcerative colitisTA1094
Guselkumab for previously treated moderately to severely active Crohn's diseaseTA1095
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and overTA1093
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancerTA1092
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsTA1091
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinomaTA1090
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)TA1089
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1088
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceTA1086
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollenTA1087
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overTA1085
Cenobamate for treating focal onset seizures in epilepsyTA753
Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)TA1082
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)TA1083
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)TA1084
Fruquintinib for previously treated metastatic colorectal cancerTA1079
Zanubrutinib for treating relapsed or refractory mantle cell lymphomaTA1081
Mirikizumab for previously treated moderately to severely active Crohn's diseaseTA1080
Dapagliflozin for treating chronic kidney diseaseTA1075
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA1077
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)TA1078
Sparsentan for treating primary IgA nephropathyTA1074
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesTA1073
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Spesolimab for treating generalised pustular psoriasis flaresTA1070
Linzagolix for treating symptoms of endometriosisTA1067
Efgartigimod for treating antibody-positive generalised myasthenia gravisTA1069
Somapacitan for treating growth hormone deficiency in people 3 to 17 yearsTA1066
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)TA1068
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA1065
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA1064
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatmentTA1063
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitorTA1062
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTA1059
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1055
Molnupiravir for treating COVID-19TA1056
Relugolix–estradiol–norethisterone for treating symptoms of endometriosisTA1057
Cladribine for treating active relapsing forms of multiple sclerosisTA1053
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and overTA1054

Results per page

  1. 10
  2. 25
  3. 50
  4. All